Active Biotech AB, Announces 2002 Results And A Rights Issue.Business Editors and Health/Medical Writers LUND, Sweden--(BUSINESS WIRE)--Feb. 17, 2003 Active Biotech AB (Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. : ACTIb.ST), a leading European biotechnology company focusing on research in and development of pharmaceuticals has announced its Quarterly Report Oct-Dec and Full Year 2002. a. Fourth quarter loss after net financial items before items affecting comparability SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 68.0 (-69,7) million b. Annual loss after net financial items SEK 308,3 (34,8) million - ongoing operations adjusted for items affecting comparability SEK -283,7 (-248,1) million c. Board decision on a SEK 225 (approx, US$ 26m) rights issue subject to the approval of the Annual General Meeting and a resolution to reduce the nominal share value, whereof MGA (1) (Monochrome Graphics Adapter) A display adapter that employs Hercules Graphics, combining graphics and text on a monochrome monitor. (2) (Matrox Graphics Accelerator) A trade name used by Matrox Graphics Inc. Holding AB guarantees issue proceeds of at least SEK 169 million. Pharmacia AB, which owns 24,1 per cent of the capital has agreed to transfer to MGA Holding AB its forthcoming subscription rights. One of the company's key projects, SAIK-MS, for the development of an orally administered medicine for the treatment of MS is going ahead according to schedule. At present, about 200 patients from various clinics in the Netherlands, England, Russia and Sweden are participating in a Phase II clinical study where just over half of the treatment weeks included in the study have been completed. The ongoing open TTS Phase IIa clinical studies of the candidate drug CD2 for renal and pancreatic cancer are going ahead according to schedule. In January FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved the start of a new clinical trials program in the USA for the next generation TTS-products, CD3. The TASQ TASQ Transparent Auto-Switch Quality (Quitum Technologies) TASQ Tactical Airlift Squadron prostate cancer project has initiated a first Phase I clinical studying collaboration with Lund University Hospital. Active Biotech's candidate drug for SLE SLE systemic lupus erythematosus. SLE abbr. systemic lupus erythematosus Systemic lupus erythematosus (SLE) - Systemic Lupus Erythematosus Systemic Lupus Erythematosus Definition Systemic lupus erythematosus (also called lupus or SLE) is a disease where a person's immune system attacks and injures the body's own organs and tissues. Almost every system of the body can be affected by SLE. - is being prepared for clinical studies during 2003. For a full Year end report and other info, please visit www.activebiotech.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion